1-20 of 74
dipeptidyl-peptidase iv inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment of Diabetes in Hospitals With Noninsulin Medications Is a Research Priority

Daisy Duan, Nestoras N. Mathioudakis, Scott J. Pilla
Journal: Diabetes Care
Diabetes Care 2024;47(6):915–917
https://doi.org/10.2337/dci23-0094
Published: 20 May 2024
View article titled, Treatment of Diabetes in Hospitals With Noninsulin Medications Is a Research Priority
Open the PDF for Treatment of Diabetes in Hospitals With Noninsulin Medications Is a Research Priority in another window
Journal Articles

Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014

Giuseppe Maltese, Alan J. Sinclair
Journal: Diabetes Care
Diabetes Care 2024;47(4):e32–e33
https://doi.org/10.2337/dc23-2420
Published: 25 March 2024
View article titled, Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014
Open the PDF for Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014 in another window
Journal Articles

Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System

Liyun He, Jialu Wang, Ziyi Li, Yuxiu Li, Huabing Zhang
Journal: Diabetes Care
Diabetes Care 2023;46(2):e72–e73
https://doi.org/10.2337/dc22-1095
Published: 19 December 2022
View article titled, Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System
Open the PDF for Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System in another window
Journal Articles

Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study

Che-Yuan Wu, Carina Iskander, Christa Wang, Lisa Y. Xiong, Baiju R. Shah, Jodi D. Edwards, Moira K. Kapral, Nathan Herrmann, Krista L. Lanctôt, Mario Masellis, Richard H. Swartz, Hugo Cogo-Moreira, Bradley J. MacIntosh, Jennifer S. Rabin, Sandra E. Black, Refik Saskin, Walter Swardfager
Journal: Diabetes Care
Diabetes Care 2023;46(2):297–304
https://doi.org/10.2337/dc22-1705
Published: 12 December 2022
View article titled, Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
Open the PDF for Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study in another window
Journal Articles

Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study

Devin Abrahami, Helen Tesfaye, Hui Yin, Seanna Vine, Blánaid Hicks, Oriana H.Y. Yu, Lysanne Campeau, Robert W. Platt, Sebastian Schneeweiss, Elisabetta Patorno, Laurent Azoulay
Journal: Diabetes Care
Diabetes Care 2022;45(12):2907–2917
https://doi.org/10.2337/dc22-1174
Published: 28 September 2022
View article titled, Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study
Open the PDF for Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study in another window
Journal Articles

Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes

Richeek Pradhan, Hui Yin, Oriana H.Y. Yu, Laurent Azoulay
Journal: Diabetes Care
Diabetes Care 2022;45(10):2289–2298
https://doi.org/10.2337/dc22-0712
Published: 22 July 2022
View article titled, Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes
Open the PDF for Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes in another window
Journal Articles

Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis

Ghadeer K. Dawwas, James H. Flory, Sean Hennessy, Charles E. Leonard, James D. Lewis
Journal: Diabetes Care
Diabetes Care 2022;45(4):919–927
https://doi.org/10.2337/dc21-2177
Published: 11 February 2022
View article titled, Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis
Open the PDF for Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis in another window
Journal Articles

Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes

Richeek Pradhan, Hui Yin, Oriana Yu, Laurent Azoulay
Journal: Diabetes Care
Diabetes Care 2022;45(4):819–829
https://doi.org/10.2337/dc21-1953
Published: 01 February 2022
View article titled, Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes
Open the PDF for Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes in another window
Journal Articles

Association Between DPP-4 Inhibitors and COVID-19–Related Outcomes Among Patients With Type 2 Diabetes

Yunha Noh, In-Sun Oh, Han Eol Jeong, Kristian B. Filion, Oriana Hoi Yun Yu, Ju-Young Shin
Journal: Diabetes Care
Diabetes Care 2021;44(4):e64–e66
https://doi.org/10.2337/dc20-1824
Published: 05 February 2021
View article titled, Association Between DPP-4 Inhibitors and COVID-19–Related Outcomes Among Patients With Type 2 Diabetes
Open the PDF for Association Between DPP-4 Inhibitors and COVID-19–Related Outcomes Among Patients With Type 2 Diabetes in another window
Journal Articles

DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials

Guillaume Grenet, Samia Mekhaldi, Sabine Mainbourg, Marine Auffret, Catherine Cornu, Jean-Luc Cracowski, François Gueyffier, Jean-Christophe Lega, Michel Cucherat
Journal: Diabetes Care
Diabetes Care 2021;44(3):e36–e37
https://doi.org/10.2337/dc20-2018
Published: 12 January 2021
View article titled, DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
Open the PDF for DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials in another window
Journal Articles

Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards

Michael A. Nauck, Juris J. Meier
Journal: Diabetes Care
Diabetes Care 2020;43(12):2906–2909
https://doi.org/10.2337/dci20-0062
Published: 08 October 2020
View article titled, Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards
Open the PDF for Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards in another window
Journal Articles

Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy

Marco Mirani, Giuseppe Favacchio, Flaminia Carrone, Nazarena Betella, Emilia Biamonte, Emanuela Morenghi, Gherardo Mazziotti, Andrea Gerardo Lania
Journal: Diabetes Care
Diabetes Care 2020;43(12):3042–3049
https://doi.org/10.2337/dc20-1340
Published: 06 October 2020
View article titled, Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy
Open the PDF for Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy in another window
Journal Articles

Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study

Oriana Hoi Yun Yu, Sophie Dell’Aniello, Baiju R. Shah, Vanessa C. Brunetti, Jean-Marc Daigle, Michael Fralick, Antonios Douros, Nianping Hu, Silvia Alessi-Severini, Anat Fisher, Shawn C. Bugden, Paul E. Ronksley, Kristian B. Filion, Pierre Ernst, Lisa M. Lix, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators, Samy Suissa, Colin R. Dormuth, Brenda R. Hemmelgarn, Jacqueline Quail, Dan Chateau, J. Michael Paterson, Jacques LeLorier, Adrian R. Levy, Pierre Ernst, Kristian B. Filion, Lisa M. Lix, Robert W. Platt, Ingrid S. Sketris
Journal: Diabetes Care
Diabetes Care 2020;43(10):2444–2452
https://doi.org/10.2337/dc20-0267
Published: 05 August 2020
View article titled, Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study
Open the PDF for Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study in another window
Journal Articles

Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study

Björn Pasternak, Viktor Wintzell, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Mads Melbye, Henrik Svanström, Peter Ueda
Journal: Diabetes Care
Diabetes Care 2020;43(6):1326–1335
https://doi.org/10.2337/dc19-2088
Published: 15 April 2020
View article titled, Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study
Open the PDF for Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study in another window
Journal Articles

Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors

Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
Journal: Diabetes Care
Diabetes Care 2019;42(11):2057–2064
https://doi.org/10.2337/dc18-2195
Published: 20 August 2019
View article titled, Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
Open the PDF for Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes

Devin Abrahami, Antonios Douros, Hui Yin, Oriana H.Y. Yu, Laurent Azoulay
Journal: Diabetes Care
Diabetes Care 2019;42(9):e150–e152
https://doi.org/10.2337/dc19-0849
Published: 11 July 2019
View article titled, Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
Open the PDF for Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes in another window
Journal Articles

Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes

Antonios Douros, Julie Rouette, Hui Yin, Oriana Hoi Yun Yu, Kristian B. Filion, Laurent Azoulay
Journal: Diabetes Care
Diabetes Care 2019;42(8):1496–1503
https://doi.org/10.2337/dc19-0409
Published: 10 June 2019
View article titled, Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
Open the PDF for Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting

Tiansheng Wang, Wenchao Lu, Dandan Li, Huilin Tang, Jeff Y. Yang, John B. Buse, Til Stürmer
Journal: Diabetes Care
Diabetes Care 2019;42(6):e89–e91
https://doi.org/10.2337/dc18-1609
Published: 10 May 2019
View article titled, Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
Open the PDF for Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting in another window
Journal Articles

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries

Peter Ueda, Björn Pasternak, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Mads Melbye, Henrik Svanström
Journal: Diabetes Care
Diabetes Care 2019;42(6):e92–e94
https://doi.org/10.2337/dc18-2532
Published: 22 April 2019
View article titled, Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries
Open the PDF for Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries in another window
Journal Articles

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39: 2042–2050

Lennart Tonneijck, Mark M. Smits, Marcel H.A. Muskiet, Trynke Hoekstra, Mark H.H. Kramer, A.H. Jan Danser, Piet M. ter Wee, Michaela Diamant, Jaap A. Joles, Daniel H. van Raalte
Journal: Diabetes Care
Diabetes Care 2019;42(3):494
https://doi.org/10.2337/dc19-er03
Published: 23 January 2019
View article titled, Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39: 2042–2050
Open the PDF for Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39: 2042–2050 in another window